|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZCCHC9 |
Gene summary for ZCCHC9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZCCHC9 | Gene ID | 84240 |
| Gene name | zinc finger CCHC-type containing 9 | |
| Gene Alias | PPP1R41 | |
| Cytomap | 5q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024RAL5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84240 | ZCCHC9 | P75T-E | Human | Esophagus | ESCC | 1.53e-22 | 4.33e-01 | 0.1125 |
| 84240 | ZCCHC9 | P76T-E | Human | Esophagus | ESCC | 3.42e-03 | 1.78e-01 | 0.1207 |
| 84240 | ZCCHC9 | P79T-E | Human | Esophagus | ESCC | 2.93e-10 | 2.35e-01 | 0.1154 |
| 84240 | ZCCHC9 | P80T-E | Human | Esophagus | ESCC | 1.90e-16 | 6.07e-01 | 0.155 |
| 84240 | ZCCHC9 | P82T-E | Human | Esophagus | ESCC | 2.12e-07 | 4.03e-01 | 0.1072 |
| 84240 | ZCCHC9 | P83T-E | Human | Esophagus | ESCC | 7.52e-15 | 5.66e-01 | 0.1738 |
| 84240 | ZCCHC9 | P89T-E | Human | Esophagus | ESCC | 1.49e-07 | 6.16e-01 | 0.1752 |
| 84240 | ZCCHC9 | P91T-E | Human | Esophagus | ESCC | 8.04e-08 | 1.30e+00 | 0.1828 |
| 84240 | ZCCHC9 | P104T-E | Human | Esophagus | ESCC | 1.79e-02 | 2.69e-01 | 0.0931 |
| 84240 | ZCCHC9 | P107T-E | Human | Esophagus | ESCC | 1.37e-18 | 4.36e-01 | 0.171 |
| 84240 | ZCCHC9 | P126T-E | Human | Esophagus | ESCC | 4.59e-02 | 3.01e-01 | 0.1125 |
| 84240 | ZCCHC9 | P127T-E | Human | Esophagus | ESCC | 1.78e-07 | 1.20e-01 | 0.0826 |
| 84240 | ZCCHC9 | P128T-E | Human | Esophagus | ESCC | 1.11e-07 | 2.35e-01 | 0.1241 |
| 84240 | ZCCHC9 | P130T-E | Human | Esophagus | ESCC | 4.48e-43 | 7.65e-01 | 0.1676 |
| 84240 | ZCCHC9 | S43 | Human | Liver | Cirrhotic | 2.06e-03 | -1.39e-01 | -0.0187 |
| 84240 | ZCCHC9 | HCC1_Meng | Human | Liver | HCC | 1.33e-55 | 6.58e-02 | 0.0246 |
| 84240 | ZCCHC9 | HCC2_Meng | Human | Liver | HCC | 8.31e-09 | -5.19e-02 | 0.0107 |
| 84240 | ZCCHC9 | HCC2 | Human | Liver | HCC | 1.22e-11 | 3.75e+00 | 0.5341 |
| 84240 | ZCCHC9 | Pt13.b | Human | Liver | HCC | 1.02e-12 | 1.23e-01 | 0.0251 |
| 84240 | ZCCHC9 | Pt14.a | Human | Liver | HCC | 2.43e-06 | 3.85e-01 | 0.0169 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZCCHC9 | SNV | Missense_Mutation | c.88G>C | p.Glu30Gln | p.E30Q | Q8N567 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZCCHC9 | insertion | Nonsense_Mutation | novel | c.682_683insGCAATCTGTCTTACTCTCACAGGCTCTTGGCTGCTT | p.Glu228delinsGlyAsnLeuSerTyrSerHisArgLeuLeuAlaAlaTer | p.E228delinsGNLSYSHRLLAA* | Q8N567 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZCCHC9 | SNV | Missense_Mutation | rs369656009 | c.527C>T | p.Pro176Leu | p.P176L | Q8N567 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZCCHC9 | SNV | Missense_Mutation | rs779203809 | c.41G>A | p.Arg14Lys | p.R14K | Q8N567 | protein_coding | tolerated(1) | benign(0) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZCCHC9 | SNV | Missense_Mutation | c.114G>C | p.Lys38Asn | p.K38N | Q8N567 | protein_coding | tolerated(0.12) | benign(0) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZCCHC9 | SNV | Missense_Mutation | rs369137521 | c.551N>T | p.Ala184Val | p.A184V | Q8N567 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZCCHC9 | SNV | Missense_Mutation | c.189N>T | p.Lys63Asn | p.K63N | Q8N567 | protein_coding | deleterious(0.01) | possibly_damaging(0.738) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZCCHC9 | SNV | Missense_Mutation | novel | c.655N>A | p.Val219Met | p.V219M | Q8N567 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZCCHC9 | SNV | Missense_Mutation | rs748879820 | c.773N>T | p.Pro258Leu | p.P258L | Q8N567 | protein_coding | tolerated(0.78) | benign(0) | TCGA-A5-A0GH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZCCHC9 | SNV | Missense_Mutation | novel | c.461C>A | p.Thr154Asn | p.T154N | Q8N567 | protein_coding | deleterious(0.02) | possibly_damaging(0.858) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |